Pneumococcal Bacterial Intramuscular or See Table A–2 None 1. For all children conjugate polysaccharides subcutaneous 2. Adults with immunocompromising conditions, asplenia, cerebrospinal vaccine conjugated to fluid leaks, or cochlear implants protein 3. Adults ≥65 years who have not been vaccinated previously Pneumococcal Bacterial Intramuscular or One dose Repeat after 1. Adults ≥65 years polysaccharide polysaccharides of subcutaneous 5 years in 2. Persons at increased risk for pneumococcal disease or its complications
Poliovirus Inactivated Subcutaneous See Table A–2 for childhood One-time booster vaccine, viruses of all three schedule. Adults: Two doses dose for adults at inactivated (IPV) serotypes 4–8 weeks apart, and a third dose increased risk of 6–12 months after the second exposure
Rabies Inactivated virus Intramuscular Preexposure: Three doses at days Serologic testing 0, 7, and 21 or 28 every 6 months to 2 years in per-
Postexposure: Four doses at days sons at high risk 0, 3, 7, and 14; immunosuppressed patients should receive a 5th dose at day 28 1. For all children 2. Previously unvaccinated adults at increased risk for occupational or travel exposure to polioviruses 1.
Preexposure prophylaxis in persons at risk for contact with rabies virus 2.
Postexposure prophylaxis (administer with rabies immune globulin in previously unvaccinated individuals)
Tetanus-Toxoids Intramuscular Two doses 4–8 weeks apart, and a Every 10 years 1. All adults diphtheria third dose 6–12 months after the 2. Postexposure prophylaxis if >5 years has passed since last dose
TABLE A–1 Materials commonly used for active immunization in the United States.1 (Continued)
Tetanus, diph-Toxoids and inac-Intramuscular Substitute one dose of Tdap for Td None All adults; pregnant women should receive a dose with each theria, pertussis tivated bacterial pregnancy (preferred during 27–36 weeks of gestation) (Tdap) components
Typhoid, Ty21a Live bacteria Oral Four doses administered every Four doses every Risk of exposure to typhoid fever oral
Typhoid, Bacterial Intramuscular One dose Every 2 years Risk of exposure to typhoid fever Vi capsular polysaccharide polysaccharide
Varicella Live virus Subcutaneous Two doses 4–8 weeks apart in Unknown 1. For all children 2. Persons past their 13th birthday without a history of varicella infection 3. Postexposure prophylaxis in susceptible persons
Yellow fever Live virus Subcutaneous One dose 10 years to 10 days Every 10 years 1. Laboratory personnel who may be exposed to yellow fever virus before travel 2. Travelers to areas where yellow fever occurs
Zoster Live virus Subcutaneous One dose None All adults ≥60 years of age 1Dosages for the specific product, including variations for age, are best obtained from the manufacturer’s package insert. 2One dose unless otherwise indicated. 3Three Hib conjugate vaccines are available for use: (1) oligosaccharide conjugate Hib vaccine (HbOC), (2) polyribosylribitol phosphate-tetanus toxoid conjugate (PRP-T), and (3) Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PRP-OMP).